Login to Your Account

XTL Shares Nearly Wiped Out After Failed Nerve Pain Study

By Catherine Hollingsworth

Wednesday, November 19, 2008
XTL Biopharmaceuticals Ltd. said that a Phase II study of its bicifadine for the treatment of diabetic nerve pain did not meet any of its objectives, causing the company's shares to fall 94.4 percent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription